Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.
Niels J M VerstegenRuth R HagenJet van den DijsselLisan H KuijperChristine KreherThomas Myles AshhurstLaura Y L KummerMaurice SteenhuisMariel DuurlandRivka de JonghNina de JongC Ellen van der SchootAmélie V BosErik MulKatherine KedzierskaKoos P J van DamEileen W StalmanLaura BoekelGertjan WolbinkSander W TasJoep KillesteinZoé L E van KempenLuuk WieskeTaco W KuijpersFilip EftimovTheo RispensS Marieke van HamAnja Ten BrinkeCarolien E van de Sandtnull nullPublished in: eLife (2022)
This research project was supported by ZonMw (The Netherlands Organization for Health Research and Development, #10430072010007), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (#792532 and #860003), the European Commission (SUPPORT-E, #101015756) and by PPOC (#20_21 L2506), the NHMRC Leadership Investigator Grant (#1173871).
Keyphrases
- multiple sclerosis
- sars cov
- rheumatoid arthritis
- end stage renal disease
- quality improvement
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- white matter
- disease activity
- ankylosing spondylitis
- patient reported outcomes
- binding protein
- systemic sclerosis
- systemic lupus erythematosus